|
BE787901A
(fr)
|
1971-09-11 |
1972-12-18 |
Freistaat Bayern Represente Pa |
Vaccin antivariolique
|
|
US4769330A
(en)
|
1981-12-24 |
1988-09-06 |
Health Research, Incorporated |
Modified vaccinia virus and methods for making and using the same
|
|
US4603112A
(en)
|
1981-12-24 |
1986-07-29 |
Health Research, Incorporated |
Modified vaccinia virus
|
|
US4722848A
(en)
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
AU570940B2
(en)
|
1982-11-30 |
1988-03-31 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Process for producing poxvirus recombinants for expression offoreign genes
|
|
GB8508845D0
(en)
|
1985-04-04 |
1985-05-09 |
Hoffmann La Roche |
Vaccinia dna
|
|
ATE181108T1
(de)
|
1991-08-26 |
1999-06-15 |
Immuno Ag |
Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus
|
|
EP1380651A2
(en)
|
1991-08-26 |
2004-01-14 |
Baxter Healthcare S.A. |
Recombinant fowlpox virus with intact FPV-tk-gene
|
|
US5445953A
(en)
|
1991-08-26 |
1995-08-29 |
Immuno Aktiengesellschaft |
Direct molecular cloning of a modified poxvirus genome
|
|
WO1994012617A1
(en)
|
1992-11-25 |
1994-06-09 |
International Biotechnology Laboratories, Inc. |
Hepatitis b virus vaccines
|
|
UA68327C2
(en)
*
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
|
EP0942747A1
(en)
|
1996-08-26 |
1999-09-22 |
Chiron Corporation |
Postinfection human immunodeficiency virus (hiv) vaccination therapy
|
|
US6962708B1
(en)
|
1997-02-28 |
2005-11-08 |
Acambis, Inc. |
Chimeric flavivirus vaccines
|
|
AUPP380598A0
(en)
|
1998-05-29 |
1998-06-25 |
Commonwealth Scientific And Industrial Research Organisation |
Genetically manipulated entomopoxvirus
|
|
US6294176B1
(en)
|
1998-07-10 |
2001-09-25 |
Schering-Plough Veterinary Corp. |
Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
|
|
US20020106798A1
(en)
|
2000-03-02 |
2002-08-08 |
Robinson Harriet L. |
DNA expression vectors and methods of use
|
|
US8623379B2
(en)
|
2000-03-02 |
2014-01-07 |
Emory University |
Compositions and methods for generating an immune response
|
|
CN100446812C
(zh)
|
2001-03-08 |
2008-12-31 |
美国国有健康与人类服务部 |
表达修饰的hiv包膜、gag和pol基因的mva
|
|
EP1279404A1
(en)
|
2001-07-26 |
2003-01-29 |
Istituto Superiore di Sanità |
Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
|
|
US20030170614A1
(en)
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
|
US7211378B2
(en)
*
|
2002-01-31 |
2007-05-01 |
Wisconsin Alumni Research Foundation |
Filovirus vectors and noninfectious filovirus-based particles
|
|
US7025970B2
(en)
|
2002-03-15 |
2006-04-11 |
Baxter International Inc. |
Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods
|
|
UA82479C2
(uk)
|
2002-05-16 |
2008-04-25 |
Бавариан Нордика А/С |
Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva)
|
|
US9045727B2
(en)
|
2002-05-17 |
2015-06-02 |
Emory University |
Virus-like particles, methods of preparation, and immunogenic compositions
|
|
US20060088909A1
(en)
|
2002-05-17 |
2006-04-27 |
Compans Richard W |
Virus-like particles, methods of preparation, and immunogenic compositions
|
|
AU2003251531A1
(en)
*
|
2002-06-14 |
2003-12-31 |
Diadexus, Inc. |
Compositions and methods relating to breast specific genes and proteins
|
|
DE10249390A1
(de)
|
2002-10-23 |
2004-05-13 |
Ruprecht-Karls-Universität Heidelberg |
Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
|
|
US20040109876A1
(en)
|
2002-11-25 |
2004-06-10 |
Kureha Chemical Industry Co., Ltd. |
Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
|
|
ATE365220T1
(de)
|
2002-11-25 |
2007-07-15 |
Bavarian Nordic As |
Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
|
|
JP5052893B2
(ja)
|
2003-02-20 |
2012-10-17 |
アメリカ合衆国 |
ポックスベクターにおける新規の挿入部位
|
|
EP1518932A1
(en)
*
|
2003-09-29 |
2005-03-30 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Modified vaccinia virus Ankara (MVA) mutant and use thereof
|
|
US20060099225A1
(en)
|
2004-04-13 |
2006-05-11 |
Sina Bavari |
Generation of virus-like particles and use as panfilovirus vaccine
|
|
AU2005285513B2
(en)
|
2004-05-25 |
2011-02-24 |
Oregon Health And Science University |
SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
|
|
WO2006026667A2
(en)
|
2004-08-27 |
2006-03-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
|
|
EP1683870A1
(en)
|
2005-01-24 |
2006-07-26 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vaccines based on the use of MVA
|
|
US8859495B2
(en)
*
|
2005-03-30 |
2014-10-14 |
Minerva Biotechnologies Corporation |
Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptors
|
|
US20060286074A1
(en)
|
2005-05-31 |
2006-12-21 |
Yucheng Tang |
Methods for immunotherapy of cancer
|
|
ES2281252B1
(es)
|
2005-07-27 |
2009-02-16 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
|
|
RU2489486C2
(ru)
|
2006-06-20 |
2013-08-10 |
Трансжене С.А. |
Процесс получения поксвирусов и композиции поксвирусов
|
|
US20100047277A1
(en)
|
2006-07-13 |
2010-02-25 |
Compans Richard W |
Virosomes, methods of preparation, and immunogenic compositions
|
|
DK2402451T3
(en)
|
2006-08-25 |
2018-06-25 |
The Government Of The Us Secretary Department Of Health And Human Services |
Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector
|
|
US20090092628A1
(en)
|
2007-03-02 |
2009-04-09 |
James Mullins |
Conserved-element vaccines and methods for designing conserved-element vaccines
|
|
AU2008275513A1
(en)
|
2007-05-02 |
2009-01-15 |
Emory University |
Enhancement of glycoprotein incorporation into virus-like particles
|
|
EP2468763B1
(en)
|
2007-05-31 |
2014-06-18 |
Academisch Ziekenhuis Leiden h.o.d.n. LUMC |
HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
|
|
US11202775B2
(en)
|
2007-09-25 |
2021-12-21 |
Minerva Biotechnologies Corporation |
Methods for treatment of cancer
|
|
US20100330190A1
(en)
|
2007-12-17 |
2010-12-30 |
Compans Richard W |
Immunogenic compositions and methods of use thereof
|
|
WO2010062757A1
(en)
|
2008-11-03 |
2010-06-03 |
Ligocyte Pharmaceuticals, Inc. |
Improved methods for isolating enveloped virus-based vlps free of infectious agents
|
|
US20120219576A1
(en)
|
2009-09-16 |
2012-08-30 |
The Administrators Of The Tulane Educational Fund |
Lassa virus-like particles and methods of production thereof
|
|
AP2012006258A0
(en)
|
2009-10-13 |
2012-06-30 |
Geovax Inc |
Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens.
|
|
WO2011047324A1
(en)
*
|
2009-10-16 |
2011-04-21 |
The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . |
Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
|
|
US20120289760A1
(en)
|
2010-01-27 |
2012-11-15 |
Hill Ann B |
Cytomegalovirus-based immunogenic preparations
|
|
AU2011217955A1
(en)
|
2010-02-18 |
2012-08-16 |
Emory University |
Vectors expressing HIV antigens and GM-CSF and related methods for generating an immune response
|
|
US20120052082A1
(en)
|
2010-04-09 |
2012-03-01 |
Zetra Biologicals, LLC |
Cross-protective influenza vaccine
|
|
WO2011130627A2
(en)
|
2010-04-16 |
2011-10-20 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Chimpanzee adenoviral vector-based filovirus vaccines
|
|
WO2011156751A2
(en)
|
2010-06-11 |
2011-12-15 |
University Of Georgia Research Foundation, Inc. |
Immunogenic vaccine
|
|
JP6169494B2
(ja)
*
|
2011-01-31 |
2017-07-26 |
ナノセラピューティクス・インコーポレイテッドＮａｎｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法
|
|
US9683020B2
(en)
|
2011-08-01 |
2017-06-20 |
Emory University |
VLPS containing ligands and methods related thereto
|
|
US20130280215A1
(en)
|
2011-10-18 |
2013-10-24 |
Geovax, Inc. |
Mva vectors expressing polypeptides and having high level production in certain cell lines
|
|
US9463238B2
(en)
|
2011-12-09 |
2016-10-11 |
Bavarian Nordic A/S |
Recombinant poxvirus vector comprising tetanus toxin fragment C
|
|
EP2869842A1
(en)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Immunogenic compositions and uses thereof
|
|
WO2014111733A1
(en)
|
2013-01-21 |
2014-07-24 |
Isis Innovation Limited |
Composition and uses thereof
|
|
WO2015009946A1
(en)
|
2013-07-17 |
2015-01-22 |
Emory University |
Method of increasing immune response to hiv antigens
|
|
AU2014340201B2
(en)
|
2013-10-23 |
2019-02-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
|
|
WO2015066715A1
(en)
|
2013-11-04 |
2015-05-07 |
Viracell Advanced Products, Llc |
Virus-like particles and methods related thereto
|
|
ES2851451T3
(es)
*
|
2014-05-13 |
2021-09-07 |
Bavarian Nordic As |
Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
|
|
CA2959105C
(en)
|
2014-09-03 |
2023-10-17 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
|
WO2016068919A1
(en)
|
2014-10-29 |
2016-05-06 |
Geovax, Inc. |
Combination therapy for treating viral reservoirs
|
|
US11701418B2
(en)
|
2015-01-12 |
2023-07-18 |
Geovax, Inc. |
Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
|
|
US10072058B2
(en)
|
2015-04-29 |
2018-09-11 |
Emory University |
Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates
|
|
CN109071592B
(zh)
*
|
2016-01-08 |
2022-07-19 |
吉奥瓦科斯公司 |
用于产生对肿瘤相关抗原的免疫应答的组合物和方法
|
|
US20190030157A1
(en)
|
2016-02-03 |
2019-01-31 |
Geovax Inc. |
Compositions and Methods for Generating an Immune Response to a Flavivirus
|
|
US11098086B2
(en)
|
2016-02-16 |
2021-08-24 |
Geovax Inc. |
Multivalent HIV vaccine boost compositions and methods of use
|
|
US11052148B2
(en)
|
2016-05-30 |
2021-07-06 |
Geo Vax, Inc. |
Compositions and methods for generating an immune response to hepatitis B virus
|
|
WO2018195447A1
(en)
|
2017-04-20 |
2018-10-25 |
Geovax Labs, Inc. |
Recombinant mva-based hiv immunogens and uses thereof
|
|
US20200171141A1
(en)
|
2017-07-18 |
2020-06-04 |
Geovax, Inc. |
Compositions and Methods for Generating an Immune Response to LASV
|
|
US20210220469A1
(en)
|
2017-08-25 |
2021-07-22 |
Geovax, Inc. |
Immuno-Oncology Compositions and Methods for Use Thereof
|
|
US11311612B2
(en)
|
2017-09-19 |
2022-04-26 |
Geovax, Inc. |
Compositions and methods for generating an immune response to treat or prevent malaria
|
|
WO2020247547A1
(en)
|
2019-06-03 |
2020-12-10 |
Geovax, Inc. |
Cancer vaccine compositions and methods for use thereof
|